Baidu
map

Oncotarget:新型无毒副作用疗法可治疗多种癌症

2016-05-20 生物谷 梅斯医学

近日,刊登于国际杂志Oncotarget上的一项研究论文中,来自迈阿密大学米勒医学院的研究人员通过研究开发了一种新型无毒疗法来治疗多种类型的癌症;这种新型疗法基于2-脱氧葡萄糖(2-Deoxy-D-glucose,2-DG)和胆固醇药物非诺贝特的组合性疗法而开发。

图片摘自:www.researchandinnovation.ie

近日,刊登于国际杂志Oncotarget上的一项研究论文中,来自迈阿密大学米勒医学院的研究人员通过研究开发了一种新型无毒疗法来治疗多种类型的癌症;这种新型疗法基于2-脱氧葡萄糖(2-Deoxy-D-glucose,2-DG)和胆固醇药物非诺贝特的组合性疗法而开发。

研究者Theodore Lampidis说道,在所有实体瘤的内部核心中发现的癌细胞中的氧气水平都异常低,而正因为如此,这些癌细胞都依赖于糖酵解过程,糖酵解是一种通过分解葡萄糖来产生能量的代谢过程,这些癌细胞天生生长缓慢,而且其对常规的癌症疗法均产生耐药性,比如放疗和化疗等。

本文研究中,研究人员发现,阻断醣酵解过程的“假糖”,比如2-脱氧葡萄糖就会有选择性地饿死生长缓慢的癌细胞,同时会保留正常细胞,而正常细胞是利用其它能源来产生能量,比如脂肪和蛋白质,因为这些物质处于完全氧化状态。尽管目前该项研究还处于I期临床试验阶段,但2-脱氧葡萄糖结合常规抗癌药物的联合疗法被证明可以成功抵御癌细胞,而化疗产生的毒性副作用仍然是一个问题;本文研究中,研究人员就将药物非诺贝特同2-脱氧葡萄糖进行结合,药物非诺贝特是一种已经安全应用超过40年的用于降低人类机体胆固醇和甘油三酯水平的药物;研究结果表明,非诺贝特同2-脱氧葡萄糖的结合可以在不产生毒性副作用的前提下有效靶向作用肿瘤细胞。

研究者发现,当非诺贝特和2-脱氧葡萄糖的特殊结合就可以同时诱发两种压力效应,即能量压力和内质网应激压力,这两种压力均不能被大部分癌症所克服。由于癌细胞的自由生长及异常的微环境所致,其往往要比正常健康细胞面临更多压力,此外,2-脱氧葡萄糖还会利用万能的癌细胞特性即便增加葡萄糖摄入,当同非诺贝特结合后,组合性疗法就可以有效利用癌细胞的第二个特点即增加压力,来对癌细胞进行精确狙杀。

最后研究者Lampidis说道,我们认为这种新型的组合性疗法或可帮助治疗多种类型的癌症,对于后期开发更多有效的个体化癌症疗法提供了一定的研究基础和思路。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1824210, encodeId=352e182421031, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 25 11:58:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078787, encodeId=b97e20e8787b1, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Jan 07 15:58:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795328, encodeId=e4681e95328e7, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Aug 17 03:58:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138134, encodeId=20491381349d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:18:01 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86847, encodeId=d08e8684e30, content=思路是好的,希望能够获得成功。, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Mon May 23 08:16:00 CST 2016, time=2016-05-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1824210, encodeId=352e182421031, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 25 11:58:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078787, encodeId=b97e20e8787b1, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Jan 07 15:58:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795328, encodeId=e4681e95328e7, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Aug 17 03:58:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138134, encodeId=20491381349d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:18:01 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86847, encodeId=d08e8684e30, content=思路是好的,希望能够获得成功。, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Mon May 23 08:16:00 CST 2016, time=2016-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1824210, encodeId=352e182421031, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 25 11:58:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078787, encodeId=b97e20e8787b1, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Jan 07 15:58:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795328, encodeId=e4681e95328e7, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Aug 17 03:58:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138134, encodeId=20491381349d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:18:01 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86847, encodeId=d08e8684e30, content=思路是好的,希望能够获得成功。, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Mon May 23 08:16:00 CST 2016, time=2016-05-23, status=1, ipAttribution=)]
    2016-08-17 闆锋旦
  4. [GetPortalCommentsPageByObjectIdResponse(id=1824210, encodeId=352e182421031, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 25 11:58:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078787, encodeId=b97e20e8787b1, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Jan 07 15:58:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795328, encodeId=e4681e95328e7, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Aug 17 03:58:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138134, encodeId=20491381349d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:18:01 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86847, encodeId=d08e8684e30, content=思路是好的,希望能够获得成功。, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Mon May 23 08:16:00 CST 2016, time=2016-05-23, status=1, ipAttribution=)]
    2016-09-30 1e10c84am36(暂无匿称)

    拜读,好文

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1824210, encodeId=352e182421031, content=<a href='/topic/show?id=56a932e7800' target=_blank style='color:#2F92EE;'>#副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32778, encryptionId=56a932e7800, topicName=副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8f0715, createdName=showtest, createdTime=Sun Dec 25 11:58:00 CST 2016, time=2016-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078787, encodeId=b97e20e8787b1, content=<a href='/topic/show?id=6dbc635680d' target=_blank style='color:#2F92EE;'>#毒副作用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63568, encryptionId=6dbc635680d, topicName=毒副作用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=de89102, createdName=liuyong2980, createdTime=Sat Jan 07 15:58:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1795328, encodeId=e4681e95328e7, content=<a href='/topic/show?id=248e1e1345b' target=_blank style='color:#2F92EE;'>#target#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17134, encryptionId=248e1e1345b, topicName=target)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Wed Aug 17 03:58:00 CST 2016, time=2016-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=138134, encodeId=20491381349d, content=拜读,好文, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 30 15:18:01 CST 2016, time=2016-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=86847, encodeId=d08e8684e30, content=思路是好的,希望能够获得成功。, beContent=null, objectType=article, channel=null, level=null, likeNumber=162, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210630/bd34754d3b0046c2bd64321e47863622/81281d26ab254ed9803ad3323b1a5f2a.jpg, createdBy=0d5f1677558, createdName=yde2801fm***3926(暂无匿称), createdTime=Mon May 23 08:16:00 CST 2016, time=2016-05-23, status=1, ipAttribution=)]
    2016-05-23 yde2801fm***3926(暂无匿称)

    思路是好的,希望能够获得成功。

    0

相关资讯

BMJ:跌眼镜!降低胆固醇反而增加死亡率!

数十年来,医学界一直提倡以植物油或鱼油代替动物脂肪,降低患心血管疾病风险,牛油、肥肉、芝士均被视为不健康食物。类似这样的新闻:坏胆固醇成国人死亡首因,8种食物降低坏胆固醇,到处都是!一般认为植物油中富含亚油酸(linoleic acid),用来代替饱和脂肪酸(以动物油为代表),可以降低心血管疾病,如冠心病。 不过,美国国家卫生研究院(NIH)周三发表研究报告指,不饱和脂肪的确有效降低血液中的胆固

NEJM:无心血管疾病的中度危险人群的降压和降脂治疗

血压和低密度脂蛋白(LDL)胆固醇升高增加心血管疾病的风险。降低两者应该可以大幅降低心血管事件的风险。进行了一项2×2的阶乘设计实验,将12705名无心血管疾病的中度危险人群随机分配到瑞托伐他汀(10mg /天)或安慰剂组,和坎地沙坦(16mg/天)+氢氯噻嗪(12.5mg/天)或安慰剂组。分析报道中,我们比较了3180名受试者分配到联合治疗(瑞托伐他汀和两种降压药)以及3168名受试者分配到双安

Sci Transl Med:环糊精有望治疗动脉粥样硬化

德国等国研究人员6日在美国《科学转化医学》杂志上报告说,环状低聚糖——环糊精可起到阻止甚至减少胆固醇结晶沉积的作用,有望用于治疗动脉粥样硬化。 动脉粥样硬化是指动脉壁上沉积一层包括胆固醇结晶在内的粥样物质,使动脉弹性降低、管腔变窄,常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应,导致动脉壁出现可致命的炎症。 先前研究发现,环糊精可缓解先天性糖脂代谢性疾病——C型尼曼匹克氏症患者脑

ARCH BIOCHEM BIOPHYS:啤酒中的黄腐酚可降低体重增加和降低胆固醇

代谢综合征影响到约34%美国成年人的健康状况,这使他们面临心血管疾病,糖尿病,中风等疾病的风险。现在,俄勒冈州立大学的研究人员说,在啤酒花和啤酒中发现一种黄酮类化合物可以减少体重增加,改善代谢综合征的指标。该研究结果发表在生物化学和生物物理学杂志上。由Cristobal Miranda(该大学的副教授)领导的研究人员发现了啤酒花类黄酮类化合物,被称为黄腐酚,其可改善实验小鼠的代谢综合征指标。根据美

盘点:脂质与心血管疾病千丝万缕的关系

当前,我国冠心病的发病率和死亡率持续快速上升,心血管疾病防控面临严峻挑战,而与心脑血管疾病密切相关的便是血脂。血脂是血液中胆固醇、甘油三酯(TG)和类脂的总称,是维持人体正常生命活动所必需的。总胆固醇(TC)又被分为高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C),其中LDL-C与心脑血管病关系最密切。 血脂异常指LDL-C、TG过高或HDL-C过低的情况,可对人体

Oncogene:“绑架”胆固醇 让胰腺癌细胞无处可逃

控制胰腺癌细胞内的胆固醇代谢就能够抑制癌细胞转移,这表明之前用于治疗动脉粥样硬化的治疗药物或将有新用途。 普渡大学的华人科学家Ji-Xin Cheng表示:“我们首次证明如果能够控制胆固醇代谢就可以抑制胰腺癌向其他器官的转移。胰腺癌是所有癌症类型中最具侵袭性的一种,因此我们选择以胰腺癌为研究对象对该方法进行检测。” Ji-Xin Cheng早先带领研究团队发现前列腺癌的侵袭性与细胞内胆固

Baidu
map
Baidu
map
Baidu
map